Abstract
Sulbactam–durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii–calcoaceticus complex (ABC) in patients 18 years of age and older. Sulbactam is a penicillin derivative with antibacterial activity against Acinetobacter but is prone to hydrolysis by β-lactamases encoded by contemporary isolates. Durlobactam is a diazabicyclooctane β-lactamase inhibitor with activity against Ambler classes A, C and D serine β-lactamases that restores sulbactam activity both in vitro and in vivo against multidrug-resistant ABC. Sulbactam–durlobactam is a promising alternative therapy for the treatment of serious Acinetobacter infections, which can have high rates of mortality.
| Original language | American English |
|---|---|
| Pages (from-to) | 563-576 |
| Number of pages | 14 |
| Journal | Future Microbiology |
| Volume | 19 |
| Issue number | 7 |
| DOIs | |
| State | Published - 2024 |
ASJC Scopus subject areas
- Microbiology
- Microbiology (medical)
Keywords
- Acinetobacter baumannii
- carbapenem resistance
- pneumonia
- sulbactam–durlobactam
- β-lactamase inhibitor
Fingerprint
Dive into the research topics of 'Sulbactam–durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver